Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2024 08:00 ET | Source: Korro Bio, Inc.

Korro to Present at the TD Cowen 44th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., will present at the TD Cowen...
January 18, 2024 08:00 ET | Source: Korro Bio, Inc.

Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio

KRRO-110 has a potentially best-in-class profile with secretion of ~50µM functional AAT protein after a single dose in a preclinical mouse modelEvidence of greater than 40% editing of SERPINA1 RNA in...
January 04, 2024 08:00 ET | Source: Korro Bio, Inc.

Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., will present at the 42nd...
December 07, 2023 08:00 ET | Source: Korro Bio, Inc.

Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

KRRO-110 is the first RNA editing oligonucleotide candidate from Korro’s proprietary OPERA™ platform Korro has demonstrated the ability to repair the misfolding of the Alpha-1 Antitrypsin (A1AT)...
November 28, 2023 08:00 ET | Source: Korro Bio, Inc.

Korro Bio Appoints Dr. Rachel Meyers to Board of Directors

Biotech veteran brings more than two decades of life science experience to Korro’s Board CAMBRIDGE, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a...
November 03, 2023 15:31 ET | Source: Korro Bio, Inc.

UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Korro will be focused on advancing a wholly owned portfolio of RNA editing programsPost-transaction cash of approximately $170 million expected to fund operations into 2026Funds multiple potentially...
November 03, 2023 12:19 ET | Source: Korro Bio, Inc.

Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Korro will be focused on advancing a wholly owned portfolio of RNA editing programsPost-transaction cash of approximately $170 million expected to fund operations into 2026Funds multiple potentially...
October 25, 2023 08:00 ET | Source: Korro Bio, Inc.

Korro Bio Announces Appointment of Tim Pearson to Board of Directors Upon Closing of the Proposed Merger and Promotion of Todd Chappell to Chief Operating Officer

Tim Pearson, CEO of Carrick Therapeutics and ex-CFO of TESARO, will join as Director contingent on the close of the proposed merger with FrequencyTodd Chappell is elevated to role of Chief Operating...